Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;13(2):215-221.
doi: 10.30466/vrf.2021.134713.3019. Epub 2022 Jun 15.

Introducing a noninvasive, non-surgical, and reversible animal model for fecal incontinence using abobotulinumtoxinA in dogs

Affiliations

Introducing a noninvasive, non-surgical, and reversible animal model for fecal incontinence using abobotulinumtoxinA in dogs

Mohammad Yasan Bangash et al. Vet Res Forum. 2022 Jun.

Abstract

The aim of this study was to introduce a new animal model of fecal incontinence (FI) by injecting abobotulinumtoxinA in the external anal sphincter (EAS) muscle of dogs which replaces models based on anal sphincter destructions that are invasive, mostly require surgical procedures, expensive, permanent, and painful to the animals. 4 healthy mongrel dogs were used in this study. First, they were received NaCl 0.09% (as control) injections in EAS muscle and effects were assessed by means of Electromyography (EMG) and clinically evaluated by sphincter pinch test and presence of leakage of feces for 2 weeks. Then, they received abobotulinumtoxinA in EAS muscle and reevaluated for 6 weeks to see short-term and medium-term effects of abobotulinumtoxinA injection. Saline had no significant changes in results obtained from EMG, however, there were significant decreases in amplitudes of action potentials after receiving abobotulinumtoxinA in comparison with no injection or saline injection in EAS muscle. Pinch tests were normal after saline injection assessment period, however, then started to be negative, ranging from two days after abobotulinumtoxinA injection to seven days after receiving abobotulinumtoxinA. Animals also had significant presentations of fecal incontinence (leakage of feces and cage contamination with feces) from the 1st week after receiving abobotulinumtoxinA until the 6th week after receiving abobotulinumtoxinA. AbobotulinumtoxinA caused paralysis in the EAS and producd FI conditions in dogs. This animal model was an appropriate substitute to the various invasive, expensive and also complicated procedures with an easy, feasible, noninvasive and non-painful single-stage abobotulinumtoxinA injection.

Keywords: AbobotulinumtoxinA; Dog; Electromyography; External anal sphincter; Fecal incontinence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Perineal view in the EMG test in dogs. A: The point of insertion of bipolar needle-EMG over the anatomical position of the pudendal nerve (hatched line). B: The point of insertion of “Ground electrode”. C: The position of placement of “Reference electrode” over the inactive region of the perineum, and D: The “Active electrode” positioned over the belly of external anal sphincter muscle
Fig. 2
Fig. 2
Perineal view of dogs during injections of saline and abo-botulinumtoxinA. A: The insertion point of Ambu© Neuroline Inject EMG needle as the cathode electrode over the belly of external anal sphincter. B: The point of insertion of anode electrode in midline, and C: The point of insertion of ground electrode
Fig. 3
Fig. 3
schematic change in voltage of amplitudes of EMG tests before treatment and time points after treatment with saline and abobotulinumtoxinA (Bot.).

Similar articles

References

    1. Paquette IM, Varma MG, Kaiser AM, et al. The American Society of Colon and Rectal Surgeons’ clinical practice guideline for the treatment of fecal incontinence. Dis Colon Rectum. 2015;58(7):623–636. - PubMed
    1. Whitehead WE, Rao SS, Lowry A, et al. Treatment of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases workshop. Am J Gastroenterol. 2015;110(1):138–146. - PubMed
    1. Johanson JF, Lafferty J. Epidemiology of fecal incontinence: the silent affliction. Am J Gastroenterol. 1996;91(1):33–36. - PubMed
    1. Rao SS. American College of Gastroenterology Practice Parameters Committee Diagnosis and management of fecal incontinence American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol. 2004;99(8):1585–1604. - PubMed
    1. Saldana Ruiz N, Kaiser AM. Fecal incontinence - Challenges and solutions. World J Gastroenterol. 2017;23(1):11–24. - PMC - PubMed

LinkOut - more resources